| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: | | | | | | | | |
| Finance receivable interest income, including fees | 35.5 | 39.3 | 30.8 | 30.1 | 26.0 | 26.9 | 15.7 | 17.3 |
| Pharmaceutical development | 5.5 | 16.1 | 5.9 | 0.6 | | | | |
| Other | 0.5 | 0.7 | 0.0 | 0.0 | 0.0 | | | |
| Total revenues | 41.5 | 56.2 | 36.7 | 30.7 | 26.0 | 37.5 | 22.4 | 23.5 |
| Total revenues growth | -26.1% | 53.0% | 19.4% | 18.3% | -30.7% | 67.5% | -4.6% | 34.8% |
| Costs and expenses: | | | | | | | | |
| Interest expense | -0.3 | -0.4 | -0.5 | -0.3 | -0.2 | | | -0.4 |
| Pharmaceutical manufacturing, research and development expense | 7.0 | 7.3 | 4.3 | 1.2 | | | | |
| Depreciation and amortization expense | 2.6 | 4.1 | 12.1 | 5.0 | 0.0 | | | |
| General and administrative | 13.0 | 13.6 | 10.5 | 7.4 | 4.9 | 4.1 | 2.8 | 3.4 |
| Income from operations | 32.5 | 31.0 | 31.9 | 16.1 | 19.1 | 12.6 | 12.6 | 21.2 |
| |
| Other income (expense), net | | | | | | | | |
| Unrealized net gain (loss) on warrants | 0.4 | 0.3 | -0.6 | 0.4 | 0.5 | -1.1 | 0.6 | -3.3 |
| |
| Gain on foreign currency transactions | | | | | | | | |
| Income before income tax expense | 9.5 | 33.0 | 3.7 | 16.8 | 6.2 | 24.0 | 10.4 | -1.1 |
| Income tax expense | -4.0 | 7.1 | -1.5 | -7.0 | 0.0 | 15.8 | -21.6 | 3.3 |
| Tax rate | | 21.5% | | | 0.7% | 65.6% | | |
| Net income | 13.5 | 25.9 | 5.2 | 23.8 | 6.2 | 8.3 | 32.0 | -4.4 |
| |
| Net income per share | | | | | | | | |
| Basic | $1.05 | $2.03 | $0.40 | $1.85 | $0.47 | $0.23 | $2.22 | ($0.57) |
| Diluted | $1.05 | $2.02 | $0.40 | $1.85 | $0.47 | $0.23 | $2.22 | ($0.57) |
| |
| Basic | 12.8 | 12.8 | 12.9 | 12.9 | 13.1 | 13.0 | 13.0 | 13.0 |
| Diluted | 12.9 | 12.8 | 12.9 | 12.9 | 13.1 | 13.0 | 13.0 | 13.0 |